{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:44:14Z","timestamp":1787867054975,"version":"build-2784847793"},"reference-count":31,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction\u2010associated steatotic liver disease (MASLD) and metabolic dysfunction\u2010associated steatohepatitis (MASH) are major health burdens. Previous reviews of semaglutide found inconsistent fibrosis improvement. This study aims to provide updated evidence on the efficacy and safety of semaglutide in MASH through a systematic review and meta\u2010analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Following PRISMA guidelines (PROSPERO: CRD420261288562), we searched databases through 8 January 2026. Ten studies (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091908) were analysed. Primary outcomes were histological MASH resolution and fibrosis improvement; secondary outcomes included liver stiffness and biochemical markers.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Semaglutide significantly improved MASH resolution without worsening fibrosis (OR 3.48; 95% CI: 2.68\u20134.53;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.00001). However, pooled fibrosis improvement (\u22651 stage) was not statistically significant (OR 1.17; 95% CI: 0.49\u20132.80;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.72). Radiologically, semaglutide reduced liver stiffness (MD \u22121.25\u2009kPa; 95% CI: \u22122.18 to \u22120.32;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009.009) and increased relative liver fat reduction of \u226530% (OR 7.16; 95% CI: 3.08\u201316.64;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u2009.00001). Significant reductions in AST, ALT and cholesterol were also observed. Regarding safety, semaglutide was associated with a higher risk of gastrointestinal\u2010related adverse events (RR\u2009=\u20091.83; 95% CI: 1.20\u20132.79) compared with the control group, but no significant difference was observed in the risk of serious adverse events (RR\u2009=\u20091.07; 95% CI: 0.82\u20131.39).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Semaglutide effectively resolves steatohepatitis and improves biochemical and imaging markers. However, its anti\u2010fibrotic efficacy appears stage\u2010dependent and time\u2010dependent, with significant histological reversal primarily observed in non\u2010cirrhotic stages within current trial durations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70629","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T10:36:15Z","timestamp":1781174175000},"page":"2584-2593","source":"Crossref","is-referenced-by-count":1,"title":["Clinical evidence of semaglutide for metabolic dysfunction\u2010associated steatotic liver disease (MASLD): An updated meta\u2010analysis"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0754-5682","authenticated-orcid":false,"given":"Tzu\u2010Rong","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Pharmacy Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation  New Taipei City Taiwan"},{"name":"School of Pharmacy, College of Pharmacy Taipei Medical University  Taipei Taiwan"},{"name":"Tzu Chi University  Hualien Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung\u2010Hong","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Chia\u2010Nan University of Pharmacy and Science  Tainan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu\u2010Ling","family":"Tseng","sequence":"additional","affiliation":[{"name":"Tzu Chi University  Hualien Taiwan"},{"name":"CardioVascular Research Center Buddhist Tzu Chi General Hospital  Hualien Taiwan"},{"name":"Department of Medical Research, Hualien Tzu Chi Hospital Buddhist Tzu Chi Medical Foundation  Hualien Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta\u2010Wei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation  New Taipei City Taiwan"},{"name":"Department of Pharmacy and Master Program Tajen University  Yanpu Pingtung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You\u2010Chen","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation  New Taipei City Taiwan"},{"name":"School of Medicine Tzu Chi University  Hualien Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102849"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i37.5327"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.18331"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197\u20102456(86)90046\u20102"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15538"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.04.003"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.12780"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rce.2022.11.007"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16608"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12080186"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(23)00068\u20107"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.013"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu14214673"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27678"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100032\u20101306421"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2147\/hmer.s7394"},{"issue":"11","key":"e_1_2_9_26_1","first-page":"660","article-title":"Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD","volume":"15","author":"Tapper EB","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32204"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010018\u20100104\u20109"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70407"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11020073"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100253"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70629","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:27:00Z","timestamp":1785371220000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/bcp.70629"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70629","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}